Statin regulation of CYP3A4 and CYP3A5 expression

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 1017-1024

  Vieira Willrich, Maria Alice ^a   Hirata, Mario Hiroyuki ^a   Crespo Hirata, Rosario Dominguez ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CYP3A4; CYP3A5; Gene expression; Pharmacogenomics; SNPs statins

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SUBSTRATE; FIBROMYALGIA; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER TOXICITY; MUSCLE INJURY; MUSCLE WEAKNESS; MYOPATHY; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 69049099092     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.42     Document Type: Article

References (51)

1. Brown CM, Reisfeld B, Mayeno AN: Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab. Rev. 40(1), 1-100 (2008).
2. Zanger UM, Turpeinen M, Klein K, Schwab M: Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008).
3. Wang K, Chen S, Xie W, Wan YJ: Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem. Pharmacol. 75(11), 2204-2213 (2008).
4. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
5. Koch I, Weil R, Wolbold R et al.: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30(10), 1108-1114 (2002).
6. Lin YS, Dowling LS, Quigley SD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62(1), 162-171 (2002).
7. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76(6), 545-556 (2004).
8. Anglicheau D, Legendre C, Beaune P, Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7), 835-849 (2007).
9. Jin Y, Wang YH, Miao J et al.: Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin. Pharmacol. Ther. 82(5), 579-585 (2007).
10. Josephson F, Allqvist A, Janabi M et al.: CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81(5), 709-712 (2007).
11. Cavalli SA, Hirata MH, Mirata RDC: Detection of MboII polymorphisin at the 5′promoter region of CYP3A4. Clin. Chem. 47(2), 348-351 (2001).
12. Fiegenbaum M, da Silveira FR, Van der Sand CR et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78, 551-559 (2005).
13. Cavalli SA, Rebecchi IMM, Matsumoto LO et al.: Lowering cholesterol response to atorvastatin is not influenced by CYP3A4*1B. Biofarma 3(6), 29-35 (2008).
14. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C: Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8(10), 1299-1306 (2007).
15. Willrich MAV, Hirata MH, Genvigir FD et al.: CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin. Chim. Acta 398(1-2), 15-20 (2008).
16. Vaughan CJ, Gotto AM Jr: Update on statins: 2003. Circulation 110, 886-892 (2004).
17. Liao JK, Laufs U: Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118 (2005).
18. Danesh FR, Kanwar YS: Modulatory effects of HMG-coA reductase inhibitors in diabetic microangiopathy. FASEB J. 18, 905-915 (2004).
19. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80 (6), 565-581 (2006).
20. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG: Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38 (9), 1240-1251 (2008).
21. Mangravite LM, Thorn CN, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6(6), 360-374 (2006).
22. Grube M, Köck K, Oswald S et al.: Organic anion transporter polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80(6), 607-620 (2006).
23. Rodrigues AC, Hirata MH, Hirata RDC: The genetic determinants of atorvastatin response. Curr. Opin. Mol. Ther. 9 (6), 545-553 (2007).
24. Kim KA, Park PW, Lee OJ, Kang BS: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin. Pharmacol. 47, 87-93 (2007).
25. Salazar LA, Cavalli SA, Hirata MH et al.: Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia. Braz. J. Med. Biol. Res. 33(11), 1301-1304 (2000).
26. Guzmán EC, Hirata MH, Quintão EC, Hirata RDC: Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high-risk for coronary heart disease. Clin. Chem. Lab. Med. 38 (8), 731-736 (2000).
27. Sorkin SC, Forestiero FJ, Hirata MH et al.: APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin. Chem. Lab. Med. 43, 1339-1345 (2005).
28. Arazi SS, Genvigir FD, Willrich MA et al.: Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin. Chim. Acta 393(2), 119-124 (2008).
29. Genvigir FD, Soares SA, Hirata MH et al.: Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin. Chim. Acta 389, 79-86 (2008).
30. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: CYP3A4 genotypes and plasma lipoprotein levels before and treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93, 104-107 (2004).
31. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (23), 2821-2827 (2004).
32. Schuetz EG: Lesson from the CYP3A4 promoter. Mol. Pharmacol. 65(2), 279-281 (2004).
33. Kivisto KT, Niemi M, Schaeffeler E et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525 (2004).
34. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, (23 Suppl. 1), III50-III57 (2004).
35. Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R: Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr. Drug Saf. 2(1), 47-63 (2007).
36. Wilke RA, Moore JH, Burmester JK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 15, 415-421 (2005).
37. Corsini A: The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 17(3), 265-285 (2003).
38. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA: Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A in hibitors in primary cultured human hepatocytes. Drug Metab. Dispos. 30 (12), 1400-1405 (2002).
39. Watanabe M, Kumai T, Matsumoto N et al.: Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J. Pharmacol. Sci. 94, 459-462 (2004).
40. Takagi S, Nakajima M, Mohri T, Yokoi T: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283 (15), 9674-9680 (2008).
41. Willrich MAV, Hirata MH, Rodrigues AC et al.: CYP3A4 and CYP3A5 mRNA expression are affected by atorvastatin in HepG2 cell line. Fourth Santorini Conference Biologie Prospective 2008, Santorini, Greece, Sep 21-23, 2008. Clin. Chem. Lab. Med. 46(8), A143 (2008).
42. Christians U, Schmitz V, Hascke M: Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol. 1(4), 641-654 (2005).
43. Lehmann JM, McKee DD, Watson MA, Wilson TM, Moore JT, Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYMP3A4 gene expression and cause drug interactions. J Clin. Invest. 102 (5), 1016-1023 (1998).
44. Wagner M, Halilbasic E, Marschall HU et al.: CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42(2), 420-430 (2005).
45. Kobayashi K, Yamanaka Y, Iwazaki N et al.: Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab. Dispos. 33 (7), 924-929 (2005).
46. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62 (2), 359-365 (2002).
47. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56 (6), 1329-1339 (1999).
48. Martin P, Riley R, Back DJ, Owen A: Comparison of the induction profile for drug disposition by typical nuclear receptor activators in human hepatic and intestinal cells. Br. J. Pharmacol. 153 (4), 805-819 (2008).
49. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5, 243-272 (2004).
50. Burk O, Wojnowski L: Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol. 369, 105-124 (2004).
51. Krusekopt, S, Roots I, Kleeber U: Differential drug-induced mRNA expression of human CYP3A4 compared with CYP3A5, CYP3A7 and CYP3A43. Eur. J. Pharmacol. 466 (1-2), 7-12 (2003).